Privium Fund Management B.V. Boosts Stake in Biogen Inc. $BIIB

Privium Fund Management B.V. raised its stake in shares of Biogen Inc. (NASDAQ:BIIB) by 153.3% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 51,925 shares of the biotechnology company’s stock after buying an additional 31,425 shares during the quarter. Biogen comprises about 1.3% of Privium Fund Management B.V.’s investment portfolio, making the stock its 16th biggest position. Privium Fund Management B.V.’s holdings in Biogen were worth $7,274,000 as of its most recent filing with the SEC.

Other institutional investors also recently made changes to their positions in the company. CVA Family Office LLC lifted its holdings in Biogen by 18.1% in the 3rd quarter. CVA Family Office LLC now owns 464 shares of the biotechnology company’s stock valued at $65,000 after purchasing an additional 71 shares in the last quarter. TD Private Client Wealth LLC lifted its stake in shares of Biogen by 22.5% during the third quarter. TD Private Client Wealth LLC now owns 414 shares of the biotechnology company’s stock valued at $58,000 after buying an additional 76 shares during the period. CX Institutional boosted its position in Biogen by 6.1% during the third quarter. CX Institutional now owns 1,453 shares of the biotechnology company’s stock worth $204,000 after acquiring an additional 83 shares during the last quarter. Rothschild Investment LLC boosted its position in Biogen by 64.7% during the second quarter. Rothschild Investment LLC now owns 224 shares of the biotechnology company’s stock worth $28,000 after acquiring an additional 88 shares during the last quarter. Finally, True Wealth Design LLC grew its stake in Biogen by 62.9% in the 3rd quarter. True Wealth Design LLC now owns 233 shares of the biotechnology company’s stock worth $33,000 after acquiring an additional 90 shares during the period. 87.93% of the stock is owned by institutional investors and hedge funds.

Biogen Stock Performance

Shares of BIIB stock opened at $179.89 on Friday. The company has a current ratio of 2.72, a quick ratio of 2.04 and a debt-to-equity ratio of 0.35. The company has a market cap of $26.39 billion, a PE ratio of 16.40, a P/E/G ratio of 1.47 and a beta of 0.13. The company’s fifty day simple moving average is $176.47 and its 200-day simple moving average is $154.62. Biogen Inc. has a 52 week low of $110.04 and a 52 week high of $190.20.

Biogen (NASDAQ:BIIB) last announced its quarterly earnings results on Thursday, October 30th. The biotechnology company reported $4.81 earnings per share for the quarter, topping analysts’ consensus estimates of $3.89 by $0.92. Biogen had a net margin of 15.98% and a return on equity of 14.13%. The firm had revenue of $2.53 billion during the quarter, compared to analysts’ expectations of $2.34 billion. During the same period in the prior year, the company earned $4.08 EPS. The firm’s revenue was up 2.8% on a year-over-year basis. As a group, equities research analysts anticipate that Biogen Inc. will post 15.83 EPS for the current year.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on BIIB. UBS Group initiated coverage on Biogen in a report on Tuesday, January 6th. They set a “neutral” rating and a $185.00 price objective on the stock. Sanford C. Bernstein increased their target price on Biogen from $157.00 to $197.00 and gave the stock a “market perform” rating in a research report on Friday, January 9th. Stifel Nicolaus upgraded Biogen from a “hold” rating to a “buy” rating and lifted their price target for the company from $144.00 to $202.00 in a report on Thursday, November 6th. Robert W. Baird cut their price objective on shares of Biogen from $255.00 to $250.00 in a report on Friday, October 31st. Finally, Wells Fargo & Company raised their target price on shares of Biogen from $155.00 to $190.00 and gave the stock an “equal weight” rating in a research report on Wednesday, December 10th. Eleven equities research analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $192.81.

Biogen Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.